These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10582201)

  • 1. Immunotherapy with a mass unit Parietaria judaica extract: a tolerance study with evidence of immunological changes to the major allergen Par j 1.
    García Villalmanzo I; Hernández MD; Campos A; Giner AM; Polo F; Cortés C; Basomba A
    J Investig Allergol Clin Immunol; 1999; 9(5):321-9. PubMed ID: 10582201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
    Rossi RE; Monasterolo G; Coco G; Operti D
    Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever.
    Ortolani C; Pastorello EA; Incorvaia C; Ispano M; Farioli L; Zara C; Pravettoni V; Zanussi C
    Allergy; 1994 Jan; 49(1):13-21. PubMed ID: 8198235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of Parietaria judaica pollen allergy using natural and recombinant Par j 1 and Par j 2 allergens.
    González-Rioja R; Ferrer A; Arilla MC; Ibarrola I; Viguera AR; Andreu C; Martínez A; Asturias JA
    Clin Exp Allergy; 2007 Feb; 37(2):243-50. PubMed ID: 17250697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.
    González-Rioja R; Ibarrola I; Arilla MC; Ferrer A; Mir A; Andreu C; Martínez A; Asturias JA
    J Allergy Clin Immunol; 2007 Sep; 120(3):602-9. PubMed ID: 17561242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerance and immunological changes of chemically modified allergen vaccine of Parietaria judaica in accelerated schedules.
    Asturias JA; Ferrer A; Arilla MC; Andreu C; Madariaga B; Martínez A
    Clin Exp Immunol; 2007 Mar; 147(3):491-6. PubMed ID: 17302898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rush sublingual immunotherapy in Parietaria allergic patients.
    D'Ambrosio FP; Ricciardi L; Isola S; Savi E; Parmiani S; Puccinelli P; Musarra A
    Allergol Immunopathol (Madr); 1996; 24(4):146-51. PubMed ID: 8939269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis.
    La Rosa M; Ranno C; André C; Carat F; Tosca MA; Canonica GW
    J Allergy Clin Immunol; 1999 Aug; 104(2 Pt 1):425-32. PubMed ID: 10452766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific skin reactions induced by individual pollen preparations in hypersensitivity persons].
    Paranos S; Petrović S; Vojović I
    Srp Arh Celok Lek; 1998; 126(9-10):362-7. PubMed ID: 9863408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
    Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
    Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen.
    Park HS; Nahm DH; Kim HY; Suh YJ; Cho JW; Kim SS; Lee SK; Jung KS
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):444-8. PubMed ID: 11345290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hyposensitization for tree pollinosis on associated apple allergy.
    Herrmann D; Henzgen M; Frank E; Rudeschko O; Jäger L
    J Investig Allergol Clin Immunol; 1995; 5(5):259-67. PubMed ID: 8574432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance.
    Ferrer M; Burches E; Peláez A; Muñoz A; Hernández D; Basomba A; Enrique E; Alonso R; Cisteró-Bahima A; Martín S; Rico P; Gandarias B
    J Investig Allergol Clin Immunol; 2005; 15(4):283-92. PubMed ID: 16433210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment.
    González P; Florido F; Sáenz de San Pedro B; de la Torre F; Rico P; Martín S
    J Investig Allergol Clin Immunol; 2002; 12(4):263-71. PubMed ID: 12926186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rush immunotherapy with sublingual administration of grass allergen extract.
    Feliziani V; Marfisi RM; Parmiani S
    Allergol Immunopathol (Madr); 1993; 21(5):173-8. PubMed ID: 8160561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.